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ABSTRACT In their natural settings, CRISPR-Cas systems play crucial roles in bacte-
rial and archaeal adaptive immunity to protect against phages and other mobile ge-
netic elements, and they are also widely used as genome engineering technologies.
Previously we discovered bacteriophage-encoded Cas9-speciﬁc anti-CRISPR (Acr) pro-
teins that serve as countermeasures against host bacterial immunity by inactivating
their CRISPR-Cas systems (A. Pawluk, N. Amrani, Y. Zhang, B. Garcia, et al., Cell 167:
1829–1838.e9, 2016, https://doi.org/10.1016/j.cell.2016.11.017). We hypothesized that
the evolutionary advantages conferred by anti-CRISPRs would drive the widespread occur-
rence of these proteins in nature (K. L. Maxwell, Mol Cell 68:8–14, 2017, https://doi.org/10
.1016/j.molcel.2017.09.002; A. Pawluk, A. R. Davidson, and K. L. Maxwell, Nat Rev Micro-
biol 16:12–17, 2018, https://doi.org/10.1038/nrmicro.2017.120; E. J. Sontheimer and
A. R. Davidson, Curr Opin Microbiol 37:120–127, 2017, https://doi.org/10.1016/j.mib
.2017.06.003). We have identiﬁed new anti-CRISPRs using the same bioinformatic
approach that successfully identiﬁed previous Acr proteins (A. Pawluk, N. Amrani, Y.
Zhang, B. Garcia, et al., Cell 167:1829–1838.e9, 2016, https://doi.org/10.1016/j.cell.2016
.11.017) against Neisseria meningitidis Cas9 (NmeCas9). In this work, we report two
novel anti-CRISPR families in strains of Haemophilus parainﬂuenzae and Simonsiella
muelleri, both of which harbor type II-C CRISPR-Cas systems (A. Mir, A. Edraki, J. Lee, and
E. J. Sontheimer, ACS Chem Biol 13:357–365, 2018, https://doi.org/10.1021/acschembio
.7b00855). We characterize the type II-C Cas9 orthologs from H. parainﬂuenzae and S.
muelleri, show that the newly identiﬁed Acrs are able to inhibit these systems, and
deﬁne important features of their inhibitory mechanisms. The S. muelleri Acr is the most
potent NmeCas9 inhibitor identiﬁed to date. Although inhibition of NmeCas9 by
anti-CRISPRs from H. parainﬂuenzae and S. muelleri reveals cross-species inhibitory
activity, more distantly related type II-C Cas9s are not inhibited by these proteins. The
speciﬁcities of anti-CRISPRs and divergent Cas9s appear to reﬂect coevolution of their
strategies to combat or evade each other. Finally, we validate these new anti-CRISPR
proteins as potent off-switches for Cas9 genome engineering applications.
IMPORTANCE As one of their countermeasures against CRISPR-Cas immunity, bacte-
riophages have evolved natural inhibitors known as anti-CRISPR (Acr) proteins. De-
spite the existence of such examples for type II CRISPR-Cas systems, we currently
know relatively little about the breadth of Cas9 inhibitors, and most of their direct
Cas9 targets are uncharacterized. In this work we identify two new type II-C anti-
CRISPRs and their cognate Cas9 orthologs, validate their functionality in vitro and in
bacteria, deﬁne their inhibitory spectrum against a panel of Cas9 orthologs, demon-
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strate that they act before Cas9 DNA binding, and document their utility as off-
switches for Cas9-based tools in mammalian applications. The discovery of diverse
anti-CRISPRs, the mechanistic analysis of their cognate Cas9s, and the deﬁnition of
Acr inhibitory mechanisms afford deeper insight into the interplay between Cas9 or-
thologs and their inhibitors and provide greater scope for exploiting Acrs for
CRISPR-based genome engineering.
KEYWORDS CRISPR, Cas9, type II-C, anti-CRISPR, crRNA
Clustered, regularly interspaced, short, palindromic repeats (CRISPRs) and theirCRISPR-associated (cas) genes constitute a prokaryotic adaptive immune defense
system against foreign genetic elements such as phages and plasmids (1–3). The
components of CRISPR-Cas systems that allow recognition and destruction of invading
genetic elements are extremely diverse and form the basis for the current CRISPR-Cas
classiﬁcation framework (4), which includes two broad classes, six major types, and
many subtypes. In class 1 CRISPR-Cas systems, effector modules form a multiprotein
complex, whereas class 2 systems use a single effector protein to target foreign nucleic
acids. Cas9 is an effector protein in the best-characterized class 2 system, type II, which
is further divided into three subtypes (II-A, -B, and -C) based on Cas9 phylogeny and the
presence or absence of additional adaptation-related Cas proteins (4). Cas9 is a single-
component, RNA-guided endonuclease that employs the CRISPR RNA (crRNA) as a
sequence-speciﬁc guide to target foreign DNA (5), with the help of a trans-activating
RNA (tracrRNA) (6), which can be fused to the crRNA to form a single guide RNA (sgRNA)
(7). The robustness and ease of Cas9 programmability have greatly facilitated its rapid
adoption in genome editing and modulation (8).
Although Cas9s have attracted unprecedented attention for genome engineering
applications, their natural function in bacterial defense plays a crucial role in the
ongoing battle against phages and other invading mobile genetic elements (MGEs). As
countermeasures against such a powerful barrier, phages and MGEs have evolved
numerous, distinct strategies to overcome bacterial defenses (9). Anti-CRISPR (Acr)
proteins provide one way to directly disarm CRISPR-Cas systems. The existence of Acrs
was ﬁrst shown in phages that successfully infect Pseudomonas aeruginosa strains
despite the presence of active type I CRISPR-Cas systems and matching CRISPR spacers
(10). The sixteen reported type I Acr families (11–13) do not share common structural
similarities or sequences but are frequently encoded adjacent to putative transcrip-
tional regulator genes known as anti-CRISPR-associated (aca) genes (14). The ﬁrst type
II-speciﬁc acr genes were identiﬁed as previously uncharacterized open reading frames
(ORFs) adjacent to predicted aca genes in MGEs of bacteria harboring type II CRISPR-Cas
systems (15). Additional Acrs have been found by identifying candidate acr genes in
lysogens embedded within genomes harboring potentially self-targeting type II
CRISPR-Cas systems (16), or by screening lytic phages for the ability to resist type II
CRISPR defenses (17, 18). Type V anti-CRISPRs have also been discovered recently (13,
19). Type II and type V Acrs are of particular interest because they can potentially
provide temporal, spatial, or conditional control over Cas9- and Cas12a-based applica-
tions.
Thus far, three families of type II-C Acrs (15) and six families of type II-A Acrs (16–18)
have been reported, and inhibitory mechanisms are known in a few cases (15, 16, 20).
For instance, AcrIIA4Lmo, a type II-A Acr that can inhibit the most widely used Cas9
ortholog from Streptococcus pyogenes (SpyCas9), prevents Cas9 DNA binding (16) by
occupying the protospacer adjacent motif (PAM)-interacting domain (PID) and masking
the RuvC nuclease domain, in part via DNA mimicry (21–23). Conversely, a type II-C Acr,
AcrIIC1Nme, does not prevent target DNA binding by Neisseria meningitidis Cas9 (Nme-
Cas9, from strain 8013), but rather binds and inhibits the enzyme’s HNH nuclease
domain (20). Yet another type II-C Cas9 inhibitor, AcrIIC3Nme, prevents target DNA
binding (15) in a manner that is accompanied by NmeCas9 dimerization (20).
Because Acrs provide obvious ﬁtness advantages (24) to phages and MGEs that must
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counteract a diversity of CRISPR-Cas systems, we hypothesized that many more type II
Acrs likely remain to be discovered. Here, we identify two new type II-C Cas9 inhibitors
from strains of H. parainﬂuenzae (AcrIIC4Hpa) and S. muelleri (AcrIIC5Smu). We charac-
terize their cognate Cas9 proteins from H. parainﬂuenzae and S. muelleri and show that
these proteins are functional in vivo and in vitro. Further, we show that AcrIIC5Smu is the
most potent NmeCas9 inhibitor reported to date. While both of these Acrs inhibit DNA
binding by Cas9, including during mammalian genome editing applications, they differ
in their phylogenetic ranges of Cas9 inhibition.
RESULTS
Identiﬁcation of novel type II-C anti-CRISPR proteins. We previously developed
a “guilt-by-association” bioinformatics approach that allowed the identiﬁcation of novel
families of anti-CRISPR proteins encoded in phages and MGEs of diverse bacterial species
(14, 15, 25). In this pipeline, new acr gene candidates are identiﬁed by their proximity to
predicted helix-turn-helix (HTH) transcriptional regulator genes known as aca genes. We
began BLASTp searches with the aca2 gene (WP_028357637.1) from Brackiella oedipodis
DSM 13743 (NZ_KK211205.1) immediately downstream of AcrIIC1Boe (WP_028357638.1)
(15). We focused speciﬁcally on hits in genomes belonging to species in which type II-C
CRISPR-Cas systems are encoded, reasoning that mobile genetic elements in those
genomes would be most likely to encode anti-CRISPR activity against the type II-C Cas9
of their host. We identiﬁed ORFs encoding uncharacterized small (50- to 150-amino-
acid [aa]) proteins immediately upstream of aca2 orthologs, focusing on genomic
regions near putative phage- or MGE-associated sequences (11, 26, 27). These criteria
led us to focus on two putative Acr candidates: an 88-aa hypothetical protein in the
genome of H. parainﬂuenzae strain 146_HPAR (WP_049372635.1) and a 130-aa hypo-
thetical protein in the genome of S. muelleri strain ATCC 29453 (WP_002642161.1; see
Table S1 in the supplemental material). Both are located upstream of apparent aca2
orthologs of H. parainﬂuenzae and S. muelleri, and these orthologs share 38%
(WP_049372634.1) and 36% (WP_002642160.1) identity to B. oedipodis aca2, respec-
tively, and 51% identity to each other (Fig. 1A). AcrIIC4 has only one detectable
homolog of 97% identity in a different strain of H. parainﬂuenzae, and AcrIIC5 has
distant orthologs in Neisseria species with 30% identity (Table S2). Both strains
encode predicted type II-C CRISPR-Cas machineries with Cas9 orthologs that exhibit
59% and 62% identity with NmeCas9, respectively (Table S3). Based on these similar-
ities, the previously established abilities of some type II anti-CRISPRs to inhibit Cas9
orthologs outside their host species (15–18, 20), and the existence of apparent or-
thologs of the S. muelleri candidate Acr in multiple examples from Neisseria (Table S2),
we ﬁrst tested for anti-CRISPR activity against the well-characterized NmeCas9. We
cloned each candidate Acr sequence into a bacterial expression vector, puriﬁed recom-
binant proteins from Escherichia coli, and tested their abilities to prevent DNA cleavage
by NmeCas9 in vitro (Fig. 1B). When each of the puriﬁed candidate Acrs was added to
parallel reaction mixtures, cleavage was inhibited in a concentration-dependent man-
ner, with complete inhibition being reached at 20-fold (H. parainﬂuenzae candidate)
and 7-fold (S. muelleri candidate) molar excess of Acr (Fig. 1B). Incubation with AcrE2,
an 84-aa type I-E anti-CRISPR (14, 25) included as a negative control, did not affect
target DNA cleavage by NmeCas9. When we compared the ability of Acrs to inhibit DNA
cleavage when ﬁrst added to the apo or sgRNA-loaded forms of NmeCas9, both
candidate Acrs inhibited the two forms of NmeCas9 to a comparable extent (Fig. S1).
This observation is in contrast to previously described orthologous anti-CRISPRs
AcrIIC1Boe and AcrIIC1Nme, which were less potent when added to the NmeCas9:sgRNA
complex (Fig. S1). Because these initial tests conﬁrmed the anti-CRISPR activities of the
two candidates from H. parainﬂuenzae and S. muelleri, we named them AcrIIC4Hpa and
AcrIIC5Smu, respectively, to conform with established Acr nomenclature (11, 25).
H. parainﬂuenzae and S. muelleri encode type II-C CRISPR-Cas systems that
function in vitro. Anti-CRISPRs are most likely to inhibit the Cas9 ortholog expressed
by the same species, but to our knowledge, little was known about the Cas9 orthologs
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from H. parainﬂuenzae and S. muelleri. To address this, we characterized these type II-C
CRISPR-Cas systems (Fig. 2A). First, we identiﬁed a 1,054-aa cas9 ORF in H. parainﬂu-
enzae DSM 8978, a strain closely related to H. parainﬂuenzae 146_HPAR for which
genomic DNA sequence was available. We identiﬁed a predicted tracrRNA adjacent to
cas9 and noted that the CRISPR repeat sequence included a likely minimal promoter
that initiates transcription in the ﬂanking spacer, as found previously with other type
II-C systems (28) (Fig. 2B). The predicted transcriptional start site would yield a crRNA
with a 24-nt spacer, similar to N. meningitidis strain 8013 (29). We then used tracrRNA:
crRNA complementarity to predict an sgRNA scaffold (Fig. S2A). These components
were then used to generate expression constructs for recombinant HpaCas9 in E. coli,
and for its sgRNA via in vitro transcription, for biochemical analyses (see below).
FIG 1 Identiﬁcation and in vitro validation of two anti-CRISPR protein families. (A) Schematic of candidate anti-CRISPR
proteins and aca2 genes in the genomic context of H. parainﬂuenzae (AcrIIC4Hpa) and S. muelleri (AcrIIC5Smu). Gray genes
are associated with mobile DNA, and known gene functions are annotated as follows: “Reg” is a transcriptional regulator,
“Tail” is involved in phage tail morphogenesis, and “Tra” is a transposase. The B. oedipodis aca2 gene is used as a query
for pBLAST searches, and percent identities of aca2 orthologs are denoted. Arrows are not drawn to scale. (B) In vitro
cleavage of target DNA by the NmeCas9-sgRNA complex in the presence of anti-CRISPR protein. Preformed NmeCas9-
sgRNA RNP complex was incubated with puriﬁed anti-CRISPR proteins as indicated with AcrE2 as a negative control, AcrIIC1
as a positive control, and candidate Acrs. Then, a linearized plasmid with a protospacer and PAM sequence was added to
the reaction mixture. Molarities of anti-CRISPR protein (relative to constant Cas9 molarity) are shown at the top of each
lane, mobilities of input and cleaved DNAs are denoted on the right, and cleavage efﬁciencies (“% cleaved”) are given at
the bottom of each lane.
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Unlike H. parainﬂuenzae DSM 8978, the CRISPR-cas locus of S. muelleri ATCC 29453
appeared to be degenerate (Fig. 2B). There is no apparent cas1, and the cas2 lacks a
canonical ATG start codon. However, the cas9 ORF (1,065 aa) is intact and has all the
predicted functional domains found in other Cas9 orthologs, which suggested that
SmuCas9 itself might be active. When we attempted to deﬁne an appropriate guide
RNA scaffold for SmuCas9, we could not predict its tracrRNA (based in part on crRNA
complementarity) from nearby genomic sequences. Instead, we found an IS5 integrase
upstream of cas9, where a tracrRNA locus is often observed (Fig. 2B). Although we
FIG 2 Characterization of new type II-C Cas9 orthologs. (A) A phylogenetic tree of type II Cas9 orthologs from S. pyogenes, N. meningitidis, C. jejuni, G.
stearothermophilus, H. parainﬂuenzae, and S. muelleri. Domains are drawn to scale and colored as follows: blue, RuvC-I, -II, and -III nuclease domain; pink,
bridge-helix (BH); gray, recognition lobe (REC); yellow, HNH nuclease domain; green, PAM-interacting domain (PI). Percent identities of type II-C orthologs to
NmeCas9 are indicated. (B) Genomic architectures of CRISPR-cas loci of H. parainﬂuenzae DSM 8978 and S. muelleri ATCC 29453. The sequence of the HpaCas9
tracrRNA is shown in the inset. Individual genomic elements are not drawn to scale. (C) PAM preferences for H. parainﬂuenzae (left) and S. muelleri (right) Cas9
proteins. Frequencies of nucleotides at each PAM position were calculated and plotted as a WebLogo.
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sequenced 2 kb ﬂanking the CRISPR locus to ﬁll gaps in the genome assembly, we
could not detect a tracrRNA sequence. As an alternative, we took advantage of the
nonorthogonality of sgRNAs to closely related Cas9 orthologs (30, 31) and used the
NmeCas9 sgRNA to test the cleavage activity of SmuCas9.
To deﬁne the PAM requirements for HpaCas9 and SmuCas9, a library of short DNA
fragments containing a unique protospacer ﬂanked by 10-nt randomized PAM se-
quences was subjected to in vitro digestion using puriﬁed, recombinant Cas9 proteins
and T7-transcribed sgRNAs. Next, digested products were gel puriﬁed and deep
sequenced. PAM sequences were identiﬁed from the resulting sequencing data based
on the frequency of nucleotides at each position of the digested products. HpaCas9
had strong preference for 5=-N4GNTT-3= PAM sequence (Fig. 2C). Notably, this PAM is
similar to the consensus PAM sequence of NmeCas9 (29, 31–33, 47). We extracted
spacer sequences from the H. parainﬂuenzae 146_HPAR CRISPR locus and identiﬁed two
candidate protospacers (Fig. S2B). When we aligned the nucleotide sequences adjacent
to the protospacers, we noted that both contained a 5=-N4GATT-3=, which is consistent
with the PAM discovered in vitro (Fig. 2C and Fig. S2B). We found that SmuCas9 had
strong preference for the 5=-N4C-3= PAM sequence (Fig. 2C). This single cytosine at the
5th position from the protospacer appears to be the most critical PAM nucleotide by
far, although moderate preferences for other nucleotides at other positions cannot be
excluded from this analysis. We validated these putative PAMs by performing in vitro
cleavage of a nondegenerate substrate and conﬁrmed efﬁcient cleavage of a DNA
target bearing a 5=-N4GNTT-3= PAM for HpaCas9 and a 5=-N4C-3= PAM for SmuCas9
(Fig. 3A).
AcrIIC4Hpa and AcrIIC5Smu inhibit their native, cognate Cas9 proteins and close
orthologs in vitro and in bacteria. We next examined the ability of AcrIIC4Hpa and
AcrIIC5Smu to inhibit HpaCas9 and SmuCas9, which share 59% and 62% sequence
identity with NmeCas9, respectively (Fig. 2A and Fig. S3). Our in vitro DNA cleavage
analyses show that these Acrs can inactivate their cognate Cas9 proteins (Fig. 3A). Given
that some type II Acrs can inhibit orthologous Cas9 within the same subtype (15–18,
20), we tested Neisseria representatives of the three other type II-C Acr families
(AcrIIC1Nme, AcrIIC2Nme, and AcrIIC3Nme) for inhibition of these two newly characterized
Cas9 proteins. We found that all three of these previously characterized Acrs inhibit the
DNA cleavage activity of both HpaCas9 and SmuCas9 (Fig. 3A).
To further characterize the physical interactions of AcrIIC4Hpa and AcrIIC5Smu with
HpaCas9 and SmuCas9, we coexpressed each 6His-tagged Cas9 together with un-
tagged Acr proteins in E. coli. Using Ni2-afﬁnity chromatography, we determined that
AcrIIC4Hpa directly bound HpaCas9 and SmuCas9 (Fig. 3B). This is similar to the results
observed for the previously characterized type II-C Acrs, which are known to bind to
NmeCas9 (15, 20). In contrast, AcrIIC5Smu did not copurify with any of the tested Cas9
proteins under these conditions (Fig. 3B).
Previous work has shown that some Acrs, such as AcrIIC1 family members, inhibit Cas9s
from Campylobacter jejuni (CjeCas9) and Geobacillus stearothermophilus (GeoCas9), in ad-
dition to NmeCas9 (20). CjeCas9 shares 32% sequence identity with NmeCas9, and GeoCas9
shares 39% (Fig. 2A and Fig. S3). To determine the range of activity of AcrIIC4Hpa and
AcrIIC5Smu, we tested their inhibitory effects on type II-C Cas9s that have been validated for
mammalian genome editing. Despite the abilities of both AcrIIC4Hpa and AcrIIC5Smu to
inhibit DNA cleavage by NmeCas9 in vitro, neither prevented target DNA cleavage by
CjeCas9 or GeoCas9 (Fig. S2C).
To conﬁrm these in vitro results, we also performed E. coli-based phage targeting
assays to assess the ability of AcrIIC4Hpa and AcrIIC5Smu to inhibit the activity of the
various Cas9 orthologs. In this assay, Cas9 expressed from a plasmid in E. coli with an
sgRNA that targets phage Mu led to a reduction in phage titer of106 PFU/ml (Fig. 3C),
and we conﬁrmed the coexpression of each Acr protein (Fig. S4). AcrIIC4Hpa expression
completely inhibited the activity of HpaCas9 and decreased the activity of NmeCas9 by
100-fold (Fig. 3C). Similarly, AcrIIC5Smu expression completely inhibited the activity of
both NmeCas9 and HpaCas9 (Fig. 3C), allowing phage Mu to plaque robustly. We were
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unable to test inhibition of SmuCas9 activity in E. coli because it failed to interfere with
phage Mu plaquing even in the absence of Acr proteins, perhaps due to compromised
function in vivo with the noncognate NmeCas9 sgRNAs. Consistent with the in vitro
results, neither AcrIIC4Hpa nor AcrIIC5Smu inhibited phage targeting by GeoCas9 or
CjeCas9 while AcrIIC1 inhibited all four Cas9 orthologs (Fig. 3C). These results, together
with the in vitro DNA cleavage assays (Fig. 1), indicate that AcrIIC4Hpa and AcrIIC5Smu
exhibit cross-species inhibitor activity (based on NmeCas9 inhibition) but have a
narrower inhibitory spectrum than AcrIIC1 (20).
AcrIIC4Hpa and AcrIIC5Smu inhibit NmeCas9-mediated genome editing in mam-
malian cells. Validation of anti-CRISPR activity in vitro and in bacteria prompted us to
test whether AcrIIC4Hpa and AcrIIC5Smu inhibit genome editing in mammalian cells.
First, we used coimmunoprecipitation experiments to conﬁrm that the NmeCas9/
AcrIIC4Hpa physical interaction observed with recombinant proteins in E. coli (Fig. 3B)
can also be detected in lysates from mammalian cells (Fig. S5A). Consistent with
AcrIIC5Smu inhibition of NmeCas9 DNA cleavage activity in vitro (Fig. 1B), we also
detected AcrIIC5Smu/NmeCas9 coimmunoprecipitation in mammalian lysates (Fig. S5A),
even though puriﬁed, recombinant NmeCas9 did not pull down recombinant
AcrIIC5Smu expressed in E. coli (Fig. 3B). To assess the inhibition of NmeCas9 genome
editing, we cotransfected HEK293T cells transiently with plasmids expressing anti-
CRISPR protein, NmeCas9 and sgRNAs targeting genomic sites. We then used T7
endonuclease 1 (T7E1) digestion to estimate genome editing efﬁciency. In agreement
FIG 3 Validation of Cas9 and anti-CRISPR proteins from H. parainﬂuenzae and S. muelleri. (A) Validation of HpaCas9 and
SmuCas9 cleavage activity and inhibition by anti-CRISPR proteins in vitro. The double asterisk denotes sgRNA. (B)
Interaction between Acrs and NmeCas9, HpaCas9, and SmuCas9 is visualized by Coomassie blue staining after copuriﬁ-
cation of each 6His-tagged Cas9 and untagged Acrs from E. coli. Each Cas9 ortholog and anti-CRISPRs are indicated as
arrowheads and asterisks, respectively. (C) Plaquing of E. coli phage Mu targeted by the Nme, Hpa, Cje, or Geo Cas9 in the
presence of the anti-CRISPR proteins. Tenfold serial dilutions of phage Mu lysate were spotted on lawns of bacteria
expressing the indicated Acr proteins. Data are from one plate representative of 3 replicates.
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with our in vitro data, expression of AcrIIC4Hpa or AcrIIC5Smu reduced NmeCas9-
mediated mutagenesis to undetectable levels at both tested sites (Fig. 4A). In contrast,
they had no effect on genome editing at the same genomic sites by SpyCas9, which
belongs to the type II-A CRISPR-Cas subtype and is very distantly related to NmeCas9
(Fig. 4A). Titration of plasmids expressing AcrIIC4Hpa or AcrIIC5Smu demonstrated po-
tency against NmeCas9 that was comparable or superior to that of AcrIIC3Nme (Fig. S5B),
which had previously been deﬁned as the most potent NmeCas9 inhibitor in mamma-
lian cells (15). For more rigorous quantitation of NmeCas9 editing, we used targeted
deep sequencing at a distinct editing site (NTS1C) and detected little to no editing at
higher doses of AcrIIC4Hpa or AcrIIC5Smu plasmids (Fig. S5C).
We previously noted a discrepancy in the potency of AcrIIC3Nme, which was least
active in inhibiting N. meningitidis transformation but was most potent in cultured
FIG 4 AcrIIC4Hpa and AcrIIC5Smu inhibit genome editing by NmeCas9 in human cells. (A) T7E1 assays of
NmeCas9 or SpyCas9 editing efﬁciencies at two dual target sites (DTS3 and DTS7) upon transient plasmid
transfection of human HEK293T cells. Constructs encoding anti-CRISPR proteins were cotransfected as
indicated at the top of each lane. Mobilities of edited and unedited bands are indicated to the right, and
editing efﬁciencies (“% lesion”) are given at the bottom of each lane. The ﬁgure is a representative of
three replicates. (B) A bar graph of editing efﬁciencies measured by TIDE analysis upon RNP delivery of
NmeCas9-sgRNA and Acr into HEK293T cells. Statistical signiﬁcance was determined by two-tailed paired
Student’s t test. Means and standard deviations from three biological replicates are indicated with lines
(*, P 0.05; **, P 0.01; ***, P 0.001).
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human cells (15). To address whether anti-CRISPR expression or stability correlates with
inhibitory effect in mammalian cells, we estimated Acr protein abundance by Western
blots using lysates from HEK293T cells transiently transfected with Acr expression
plasmids (identical in all respects other than Acr ORF). Inhibition potency correlated
well with the abundance of the anti-CRISPR, with AcrIIC4Hpa and AcrIIC5Smu showing
the highest protein signal at steady state (Fig. S5D). To bypass the difference in protein
abundance, we delivered a preformed ribonucleoprotein (RNP) complex of NmeCas9,
sgRNA, and each Acr to HEK293T cells by electroporation. Then, we conﬁrmed genome
editing inhibition by AcrIIC4Hpa and AcrIIC5Smu using tracking of indels by decompo-
sition (TIDE) analysis (34) (Fig. 4B). Acrs still displayed variations in activities even with
RNP delivery, suggesting differences in protein stability, off-rate, or other intrinsic
properties. Of note, however, AcrIIC4Hpa and AcrIIC5Smu consistently exhibited strong
inhibitory potency both in vitro and in cultured cells (Fig. 1B and 4). Furthermore,
AcrIIC4Hpa and AcrIIC5Smu coexpression increased the steady-state accumulation of
NmeCas9 (with or without sgRNA coexpression), consistent with the possibility of a
stabilizing physical interaction (Fig. S5E). Overall, these data demonstrate that the two
new anti-CRISPRs directly bind to NmeCas9 and speciﬁcally inhibit its DNA cleavage
activity in human cells.
AcrIIC4Hpa and AcrIIC5Smu prevent stable DNA binding by NmeCas9. Once we
conﬁrmed the anti-CRISPR inhibition of sgRNA-guided NmeCas9 DNA cleavage in vitro
(Fig. 1) and genome editing in cells (Fig. 4), we then addressed the mechanisms of
NmeCas9 inhibition by AcrIIC4Hpa and AcrIIC5Smu. Since structural and biochemical
analysis of the anti-CRISPRs characterized to date suggests diverse and unique inhib-
itory mechanisms (11, 26, 27, 35), we tested multiple hypotheses: Acrs prevent sgRNA
loading, DNA target binding (like AcrIIC3Nme [15, 20]), or DNA target cleavage (like
AcrIIC1Nme [20]). First, we checked whether sgRNA loading onto NmeCas9 is inhibited
by either anti-CRISPR. We carried out electrophoretic mobility shift assays (EMSAs) by
incubating NmeCas9 and sgRNA with or without Acr, and then visualizing sgRNA
mobility after native gel electrophoresis by SYBR Gold staining. In the absence of any
anti-CRISPR, incubation of NmeCas9 with its cognate sgRNA resulted in a gel shift that
indicates formation of a stable RNP complex (Fig. 5A). When NmeCas9 was incubated
with a negative-control anti-CRISPR (AcrE2) before the addition of sgRNA, NmeCas9:
sgRNA complex formation was unaffected. Similarly, when incubated with AcrIIC4Hpa
and AcrIIC5Smu, efﬁcient NmeCas9:sgRNA complex formation was again observed,
suggesting that neither Acr protein signiﬁcantly affected RNP assembly.
To test if target DNA engagement by the NmeCas9:sgRNA complex is prevented by
either AcrIIC4Hpa or AcrIIC5Smu, we performed EMSAs and ﬂuorescence polarization
assays after incubating the RNP with each Acr, before adding target DNA (Fig. 5B and
Fig. S5A). To inhibit DNA target cleavage, we omitted divalent metal ions from the
reaction mixtures. While the target DNA exhibited the expected mobility shift in the
absence of Acr, or in the presence of AcrE2 or AcrIIC1Nme (as expected [20]), both
AcrIIC4Hpa and AcrIIC5Smu prevented NmeCas9 RNP binding to the target DNA. We also
performed ﬂuorescence polarization assays to measure the equilibrium binding con-
stants of NmeCas9 RNP (0 to 2 M) to target DNA (8 nM) in the presence or absence of
Acrs (10 M). As shown in Fig. S5A, AcrIIC4Hpa and AcrIIC5Smu signiﬁcantly impair the
DNA binding activity of NmeCas9:sgRNA, conﬁrming our EMSA results. The measured
Kd of the NmeCas9 RNP to this target DNA (without Acr inhibition) is 86  4 nM, similar
to a previous measurement (70 5 nM) with a different sgRNA/target site combination
(20). The addition of AcrIIC4Hpa and AcrIIC5Smu reduced apparent DNA afﬁnity by
9-fold (to 750 150 nM) and6-fold (to 450 50 nM), respectively (Fig. S5A), similar
to the 10-fold inhibition of NmeCas9 DNA binding by AcrIIC3Nme (20).
AcrIIC4Hpa and AcrIIC5Smu are potent inhibitors of dNmeCas9-based tools in
mammalian cells. Many applications (e.g., CRISPRi and CRISPRa) have been developed
for catalytically inactive (“dead”) Cas9 (dCas9) derivatives fused or tethered to various
effector domains (36). To extend our ﬁndings from in vitro studies to mammalian cells,
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FIG 5 AcrIIC4Hpa and AcrIIC5Smu prevent stable DNA binding by NmeCas9. (A and B) A native gel of the sgRNA visualized by SYBR gold
staining (A) and of the FAM-labeled target DNA (B), both of which were added last to NmeCas9 Acr (and in panel B,  sgRNA)
incubation. (C) Live-cell ﬂuorescence images of U2OS cells transiently transfected with plasmids encoding dNmeCas9-(sfGFP)3, dSpyCas9-
(mCherry)3, their respective telomeric sgRNAs, and Acrs. The plasmid encoding the Acr is also marked with the blue ﬂuorescent protein,
mTagBFP2, which is overlaid on a differential interference contrast (DIC) image of each cell. The speciﬁc version of each plasmid set (with
or without sgRNAs, with or without anti-CRISPRs) is given to the right of each row. First column, differential interference contrast (DIC)
and mTagBFP2 imaging, overlay. Second column, dNmeCas9-(sfGFP)3. Third column, dSpyCas9-(mCherry)3. Fourth column, dNmeCas9-
(sfGFP)3 and dSpyCas9-(mCherry)3, merged. Scale bars, 5 m.
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we tested whether AcrIIC4Hpa and AcrIIC5Smu prevent stable DNA binding of dNmeCas9
using previously established methods for live-cell imaging of telomeric foci. Brieﬂy,
transfection of plasmids expressing dCas9 orthologs fused to ﬂuorescent proteins, as
well as cognate sgRNAs targeting telomeres, enables telomeric foci to be visualized in
U2OS cells (37). Orthogonal dNmeCas9-(sfGFP)3 and dSpyCas9-(mCherry)3 can be used
in this fashion simultaneously to bind telomeres and generate colocalizing sfGFP and
mCherry telomeric foci (38). Transfection of a third plasmid, marked with mTagBFP2
and encoding an anti-CRISPR protein, can be used to assess the anti-CRISPR’s effects on
telomeric DNA binding in live cells (15). AcrE2 had no effect on telomeric foci formed
by dNmeCas9-(sfGFP)3 and dSpyCas9-(mCherry)3, as seen previously (15); however,
coexpression of AcrIIC4Hpa or AcrIIC5Smu resulted in loss of green foci formation by
dNmeCas9-(sfGFP)3 without abolishing the red telomeric foci formed by dSpyCas9-
(mCherry)3 (Fig. 5C). We then quantiﬁed the number of cells exhibiting telomeric
dNmeCas9-(sfGFP)3 foci in a blinded experimental setup (Fig. S5B). We observed
dNmeCas9-(sfGFP)3 foci in approximately 80% of cells in the absence of any Acr protein,
in 70% of cells expressing AcrE2 protein (negative control), and in 0% of cells in the
presence of AcrIIC3Nme (as a positive control [15, 20]) (Fig. S5B). We found that 0% of
cells exhibited dNmeCas9-(sfGFP)3 telomeric foci when the two novel anti-CRISPRs were
coexpressed (0 out of 78 for AcrIIC4Hpa and 0 out of 82 for AcrIIC5Smu) (Fig. S5B). These
results conﬁrm that AcrIIC4Hpa and AcrIIC5Smu inhibit stable DNA binding of dNmeCas9
in a cellular context, indicating their potential utility as potent off-switches for
dNmeCas9-based applications.
These data from mammalian cells conﬁrm the potential utility of AcrIIC4Hpa or
AcrIIC5Smu (as well as other type II anti-CRISPR) proteins for modulating Cas9-
dependent genome engineering applications across subtypes.
DISCUSSION
The prevalence of CRISPR-Cas immune systems in bacteria and archaea has driven
phages to evolve diverse anti-CRISPR proteins. Indeed, numerous anti-CRISPRs against
type I and type II systems have been discovered in both bacteria and archaea since the
ﬁrst examples were reported in 2013 (10), with a range of inhibitory mechanisms for
impairing Cas protein function (11, 26, 27, 35). Here, we report two new families of type
II-C anti-CRISPR proteins, AcrIIC4Hpa and AcrIIC5Smu, and their cognate Cas9 proteins
from H. parainﬂuenzae and S. muelleri. We deﬁne PAMs for the newly characterized
HpaCas9 and SmuCas9 orthologs and show that they are functional in vitro and that
HpaCas9 confers phage immunity in bacteria, expanding the functional Cas9 repertoire.
These additional anti-CRISPRs and Cas9s total ﬁve anti-CRISPR families that differentially
inactivate ﬁve different type II-C Cas9 orthologs (Fig. 6).
AcrIIC4Hpa and AcrIIC5Smu inhibit NmeCas9, HpaCas9, and SmuCas9 activity in vitro,
as well as CRISPR interference activity in bacteria, and both also prevent NmeCas9-
mediated genome editing in mammalian cells. The two new Acr families are the most
potent among the type II-C Acrs, prevent substrate DNA binding by NmeCas9 and
dNmeCas9, and exhibit higher speciﬁcities for inhibition of type II-C Cas9s in compar-
ison to AcrIIC1 (20). AcrIIC4Hpa and AcrIIC5Smu activity was found to be speciﬁc to
FIG 6 Summary of type II-C Cas9 orthologs and anti-CRISPR families. Type II-C anti-CRISPRs can act at
distinct stages of Cas9-mediated target DNA cleavage. While AcrIIC1 binds to the HNH domain and
inhibits a broad spectrum of Cas9 orthologs, AcrIIC4 and AcrIIC5 prevent DNA binding and have a
narrower range of inhibition, similar to AcrIIC3.
Potent Cas9 Inhibition by anti-CRISPR proteins ®
November/December 2018 Volume 9 Issue 6 e02321-18 mbio.asm.org 11
 o
n








closely related Cas9 orthologs, as they did not inhibit the more distantly related CjeCas9
and GeoCas9 type II-C orthologs. Cross-species inhibitory effects of each Acr may be
graded depending on the similarity of the Cas9 orthologs. Subtle differences may be
sufﬁcient to distinguish each anti-CRISPR’s breadth of inhibition as broad spectrum or
highly speciﬁc, with gradations between these two extremes. For example, the AcrIIC1
family of Acrs can inhibit multiple Cas9s, likely because they bind to the highly
conserved HNH domain (20), whereas other type II-C Acrs may bind to Cas9 domains
that are less conserved (like the PID). The evolutionary pressure on Cas9s to evolve
away from anti-CRISPR inhibition may promote diverse PAM speciﬁcities and other
mechanistic distinctions between Cas9 orthologs. This may also explain why some
hosts carry multiple, active CRISPR-Cas systems. Similarly, distinct anti-CRISPR speciﬁc-
ities for inhibiting Cas9 orthologs could suggest different mechanisms of action. We
show that AcrIIC4Hpa and AcrIIC5Smu prevent binding of Cas9 to target DNA, like AcrIIC3
and AcrIIA4 but unlike AcrIIC1 (15, 20). Target DNA binding could be prevented by
precluding initial recognition of the PAM (similar to the strategy of AcrIIA4 [21–23]), by
preventing one of the stages of R-loop formation and Cas9 structural rearrangement
(39), or a combination of these.
Moreover, we have demonstrated the potential utility of Acr-mediated control of
Cas9 and dCas9-based technologies by AcrIIC4Hpa and AcrIIC5Smu. Recently, AcrIIA4 (16)
was used as an inhibitor of dSpyCas9 fused to a DNA demethylase, Tet1, to inactivate
dSpyCas9-Tet1 DNA target binding (40). Separately, AcrIIA families were shown to
prevent a gene-drive propagation in Saccharomyces cerevisiae (41). These are a few
examples of the potential utility of Acrs as Cas9 off-switches. Many applications stand
to beneﬁt from increasing the numbers, speciﬁcities, and inhibitory mechanisms of
anti-CRISPRs, for instance through combinatorial control over multiple Cas9/dCas9
proteins. For example, both broad-spectrum (e.g., AcrIIC1Nme) and highly speciﬁc (e.g.,
AcrIIC3Nme, -4Hpa, or -5Smu) anti-CRISPR proteins could be used to control multiple Cas9s
simultaneously, or speciﬁc Cas9s but not others, upstream or downstream of target
recognition, to achieve maximal ﬂexibility of both genome manipulation and regula-
tion.
Apart from potential uses in biotechnology, CRISPR-Cas systems and anti-CRISPR
proteins that inactivate them are in strong accord with the Red Queen hypothesis,
which proposes that bacteria must evolve new mechanisms to resist invaders while the
invaders simultaneously evolve countermeasures (42). The widespread prevalence and
extreme diversity of CRISPR-Cas systems in bacteria and archaea, as well as the adaptive
nature of the resulting defenses, pose a signiﬁcant challenge to phages and other
MGEs. Anti-CRISPR proteins provide phages with an effective tactic to inactivate
CRISPR-Cas systems and likely contribute to phage persistence in the face of host
defense mechanisms. Many gaps remain in our understanding of the origins of these
anti-CRISPRs and how they function in the context of phage predation. It is likely that
these proteins have emerged independently and repeatedly through convergent evo-
lution, as indicated by a lack of sequence or structural similarities among many
reported Acrs (11, 26, 27, 35). A structural study of a capsid protein from a phage that
infects Thermus thermophilus shares a common core -barrel domain with AcrIIC1,
suggesting an evolutionary source for an anti-CRISPR protein (43). Our ability to address
these outstanding questions is limited by the relatively small number of examples of
known anti-CRISPR proteins and their striking diversity in sequence and structures.
Expanding the collection of diverse anti-CRISPR families and their cognate CRISPR
effectors will help further our understanding of the arms race between phages and
their hosts.
MATERIALS AND METHODS
Bioinformatics analysis for anti-CRISPR identiﬁcation. Putative anti-CRISPR genes were identiﬁed
using the guilt-by-association bioinformatic method described previously (15). Brieﬂy, BLASTp searches
were conducted using aca2 (WP_028357637.1) from B. oedipodis DSM 13743 (NZ_KK211205.1), and
orthologs of aca2 that had a small, uncharacterized hypothetical ORF immediately upstream were
curated manually. The search yielded two high-conﬁdence putative type II-C Acrs in strains of H.
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parainﬂuenzae 146_HPAR 254_56103_2121718_43__198__43_ (accession NZ_JVSL01000013.1) and S.
muelleri ATCC 29453 (accession NZ_CP019448.1).
Characterization of HpaCas9 and SmuCas9. CRISPRﬁnder (http://crispr.i2bc.paris-saclay.fr) was
used to identify the CRISPR locus of H. parainﬂuenzae. The spacers targeting the phage sequences were
blasted via CRISPRTarget (http://bioanalysis.otago.ac.nz/CRISPRTarget) to predict the PAM present on the
3= sequences. DNA and protein sequences of HpaCas9 and SmuCas9 orthologs are provided in Table S1
in the supplemental material.
Plasmid construction. Plasmids used in this study are described in Table S4.
Cas9/sgRNA and anti-CRISPR vector for bacterial expression, protein puriﬁcation, and in vitro
transcription. The pMCSG7-NmeCas9 expression vector and the sgRNA for in vitro transcription are as
previously described (15). To make the HpaCas9 expression vector pEJS-MCSG7-HpaCas9, genomic DNA
sequence from H. parainﬂuenzae DSM 8987 was obtained from DSMZ and cloned into the pMCSG7-
NmeCas9 expression plasmid, replacing the NmeCas9 sequence using Gibson Assembly (NEB). The
GeoCas9-expressing plasmid (expressing the GeoCas9 ortholog from G. stearothermophilus strain ATCC
7953) was obtained from Addgene (catalog no. 87700) and similarly cloned into the pMCSG7 vector. To
make GeoCas9 from G. stearothermophilus strain L300, a gBlock (IDT) containing the PID was used to
replace the PID of GeoCas9 from G. stearothermophilus strain ATCC 7953. For construction of sgRNA
scaffolds for HpaCas9 and GeoCas9, the tracrRNA was predicted by crRNA repeat complementarity as
well as homology to the NmeCas9 tracrRNA. These sgRNA scaffolds were ordered as gBlocks (IDT) along
with overhangs to clone into pLKO.1 plasmid (15, 44) using Gibson Assembly (NEB). The CjeCas9 sgRNA
plasmid was used as previously reported (20, 45). All sgRNA scaffolds were used as the templates to
create in vitro-transcribed sgRNAs.
DNA sequences encoding candidate anti-CRISPR proteins were synthesized and cloned into a pUC57
mini (AmpR) vector with an N. meningitidis 8013 Cas9 promoter sequence for bacterial work, as done
previously for other anti-CRISPRs (15). For anti-CRISPR protein puriﬁcation, the Acr insert was ampliﬁed
and inserted into the pMCSG7 backbone by Gibson Assembly (NEB), resulting in pMCSG7-Acr. Table S1
contains the DNA and protein sequences of the anti-CRISPRs tested in this study.
Cas9/sgRNA and Acr vectors for mammalian expression. For editing of genomic dual target sites
by both SpyCas9 and NmeCas9, we used Cas9 and cognate sgRNA expression vectors that were
described previously (15). To generate the Acr expression vector, the Acr ORF was ampliﬁed from
pUC57-Acr and inserted into XhoI-digested pCSDest2 by Gibson Assembly (NEB).
Vectors for ﬂuorescence microscopy. pHAGE-TO-DEST dSpyCas9-(mCherry)3 and dNmeCas9-
(sfGFP)3 plasmids (38) were purchased from Addgene (catalog no. 64108 and 64109, respectively) and
used directly for no-sgRNA control experiments. dNmeCas9-(sfGFP)3 and dSpyCas9-(mCherry)3 all-in-one
plasmids have been described previously (15). To make Acr plasmids, we ampliﬁed an mTagBFP2 cassette
and incorporated it into pCSDest2 vectors expressing the respective Acr by Gibson Assembly (NEB).
Expression and puriﬁcation of Acr and Cas9 proteins. The expression and puriﬁcation of Acrs and
Cas9s were performed as described previously (7, 15). 6His-tagged anti-CRISPRs and Cas9s were
expressed in E. coli strain BL21 Rosetta(DE3). Cells were grown in LB or 2 YT medium at 37°C to an
optical density (OD600) of 0.6 in a shaking incubator. At this stage the bacterial cultures were cooled to
18°C, and protein expression was induced by adding 1 mM IPTG. Bacterial cultures were grown overnight
at 18°C (16 h), after which cells were harvested and resuspended in lysis buffer (50 mM Tris-HCl [pH 7.5],
500 mM NaCl, 5 mM imidazole, 1 mM DTT) supplemented with 1 mg/ml lysozyme and protease inhibitor
cocktail (Sigma). Cells were lysed by sonication, and the supernatant was then clariﬁed by centrifugation
at 18,000 rpm for 30 min. The supernatant was incubated with preequilibrated Ni-NTA agarose (Qiagen)
for 1 h. The resin was then washed twice with wash buffer (50 mM Tris-HCl [pH 7.5], 500 mM NaCl, 25 mM
imidazole, 1 mM DTT). The proteins were eluted in elution buffer containing 300 mM imidazole. For Acr
proteins, the 6His tag was removed by incubation with His-tagged tobacco etch virus (TEV) protease
overnight at 4°C followed by a second round of Ni-NTA puriﬁcation to isolate successfully cleaved,
untagged anti-CRISPRs (by collecting the unbound fraction). Cas9s were further puriﬁed using cation
exchange chromatography using a Sepharose HiTrap column (GE Life Sciences). Size exclusion chroma-
tography was used to purify NmeCas9 further in 20 mM HEPES-KOH (pH 7.5), 300 mM KCl and 1 mM
TCEP.
In vitro DNA cleavage. For the in vitro DNA cleavage experiments with NmeCas9 (Fig. 1B and
Fig. S1), NmeCas9 sgRNA targeting NTS4B was generated by in vitro T7 transcription (NEB). NmeCas9
(150 nM) was incubated with puriﬁed, recombinant anti-CRISPR protein (0 to 5 M) in cleavage buffer
(20 mM HEPES-KOH [pH 7.5], 150 mM KCl, 1 mM DTT) for 10 min. Next, sgRNA (1:1, 150 nM) was added
and the mixture was incubated for another 15 min. Plasmid containing the target protospacer NTS4B was
linearized by ScaI digestion. Linearized plasmid was added to the Cas9/sgRNA complex at 3 nM ﬁnal
concentration. The reaction mixtures were incubated at 37°C for 60 min, treated with 1 U proteinase K
(NEB) at 50°C for 10 min, and visualized after electrophoresis in a 1% agarose/1 TAE gel.
Phage immunity assay. Plasmids expressing Cas9 targeting E. coli phage Mu were cotransformed
into E. coli strain BB101 with plasmids expressing the anti-CRISPRs (20). Cells carrying both plasmids were
grown in lysogeny broth (LB) supplemented with streptomycin (50 g/ml) and chloramphenicol (34 g/
ml). Anti-CRISPR gene expression was induced using 0.01 mM IPTG for three hours. A lawn of 200 l of
cells in top agar was applied to LB agar plates supplemented with streptomycin, chloramphenicol,
200 ng/ml anhydrotetracycline (aTc), 0.2% arabinose  200 ng/ml aTc, and 10 mM MgSO4. Tenfold serial
dilutions of phage Mu were spotted on top of the lawn, and the plates were incubated overnight at 37°C.
To conﬁrm the expression levels of the anti-CRISPR proteins in this assay, 500-l aliquots of cells applied
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to the top agar were pelleted by centrifugation, resuspended in 100 l of SDS-PAGE loading buffer, and
run on a 15% Tris-Tricine gel, and the resulting protein gel was visualized by Coomassie blue (Bio-Rad).
Cas9-Acr copuriﬁcation. Cas9 proteins were expressed from plasmid pMCSG7 with an N-terminal
6His afﬁnity tag in E. coli Rosetta cells. Untagged Acrs were coexpressed in the same cells from plasmid
pCDF1b. Cells were grown in LB to an OD600 of 0.8, and protein production was induced with 2 mM IPTG
overnight at 16°C. Cells were collected by centrifugation, resuspended in binding buffer (20 mM Tris, pH
7.5, 250 mM NaCl, 5 mM imidazole), and lysed by sonication, and cellular debris was removed by
centrifugation. The cleared lysates were applied to Ni-NTA columns, washed with binding buffer
supplemented with 30 mM imidazole, and eluted with 300 mM imidazole. Protein complexes were
analyzed by SDS-PAGE followed by Coomassie staining.
PAM determination. A library of a protospacer with randomized PAM sequences was generated
using overlapping PCRs, with the forward primer containing the 10-nt randomized sequence ﬂanking the
protospacer. The library was subjected to in vitro cleavage by puriﬁed recombinant HpaCas9 or SmuCas9
proteins as well as in vitro-transcribed sgRNAs. Brieﬂy, 300 nM Cas9:sgRNA complex was used to cleave
300 nM target fragment in 1 reaction buffer (NEBuffer 3.1) at 37°C for 60 min. The reaction mixture was
then treated with 1 U proteinase K (NEB) at 50°C for 10 min and run on a 4% agarose gel with 1 TAE.
The segment of a gel where the cleavage products were expected to be was puriﬁed and subjected to
library preparation as described previously (46). The library was sequenced using the Illumina
NextSeq500 sequencing platform and analyzed with custom scripts.
Electrophoretic mobility shift assay (EMSA). NmeCas9 (1 M) was incubated with 1 M sgRNA in
1 binding buffer (20 mM Tris-HCl [pH 7.5], 150 mM KCl, 2 mM EDTA, 1 mM DTT, 5% glycerol, 50 g/ml
heparin, 0.01% Tween 20, 100 g/ml BSA) for 20 min at room temperature to form the RNP complex. Acrs
were added to a ﬁnal concentration of 10 M and incubated for an additional 20 min. Finally, the
FAM-tagged NTS4B protospacer oligonucleotide was added to the mixture and incubated at 37°C for 1 h.
The mixture was loaded onto a native 6% acrylamide gel, and the FAM-tagged DNA was visualized using
a Typhoon imager.
sgRNA EMSA. NmeCas9 (1.5 M) and anti-CRISPR (20 M) proteins were preincubated in 1 binding
buffer for 10 min, and then sgRNA (0.15 M) was added to the reaction mixture for an additional 10 min.
The complexes were resolved on a 6% polyacrylamide native gel, stained by SYBR Gold (ThermoFisher),
and visualized with a Typhoon imager.
Mammalian genome editing. Plasmids for mammalian expression of NmeCas9, SpyCas9, their
respective sgRNAs, and the anti-CRISPR proteins are listed in Table S4. Plasmid transfections, collection
of genomic DNA, and T7E1 digestions were as described previously (15).
Genome editing by Cas9 ribonucleoprotein (RNP) delivery. RNP delivery of NmeCas9 was
performed using a Neon electroporation system following the manufacturer’s instructions (Thermo-
Fisher). Brieﬂy, in a 10 l reaction volume, 15 pmol of NmeCas9 and 150 pmol of anti-CRISPR protein were
mixed in buffer R and incubated at room temperature for 20 min. Then, 20 pmol of T7 in vitro-transcribed
sgRNA was added to the Cas9-Acr complex and incubated at room temperature for 30 min. Approxi-
mately 50,000 to 100,000 cells were mixed with the RNP-Acr-sgRNA complex, electroporated (Neon
nucleofection system), and then plated in 24-well plates. Genomic DNA was extracted 48 h post-
nucleofection using a DNeasy Blood and Tissue kit (Qiagen) according to the manufacturer’s protocol.
Quantiﬁcation of editing (% of amplicons exhibiting lesions) was done using TIDE analysis (34). PCR
products spanning the target site were ampliﬁed using 2 Q5 master mix (NEB) and column-puriﬁed
(Zymo). Puriﬁed amplicons were sent for Sanger sequencing (Genewiz), and trace ﬁles were analyzed by
TIDE.
Fluorescence microscopy of dNmeCas9. Experimental procedures were as described previously
(15). Brieﬂy, U2OS cells were cotransfected with all-in-one plasmids (150 ng of each dNmeCas9 and
dSpyCas9 plasmid), additional sgRNA-expressing plasmid, and 100 ng of anti-CRISPR/mTagBFP2 plasmid
using PolyFect (Qiagen) according to the manufacturer’s instructions. After 24 h of incubation, live cells
were imaged with a Leica DMi8 microscope equipped with a Hamamatsu camera (C11440-22CU), a 63
oil lens objective, and Microsystems software (LASX). Further imaging processing was done with
Fiji-ImageJ. For quantiﬁcation, only cells that exhibited mTagBFP2 and sfGFP ﬂuorescence as well as
dSpyCas9-(mCherry)3 telomeric foci were assessed for the presence or absence of colocalizing
dNmeCas9-(sfGFP)3 telomeric foci.
Fluorescence polarization. For ﬂuorescence polarization assays, preformed RNP complex of Nme-
Cas9 and sgRNA was added to 1 binding buffer (20 mM Tris-HCl [pH 7.5], 150 mM KCl, 5 mM EDTA,
5 mM MgCl2, 1 mM DTT, 5% [vol/vol] glycerol, 50 g/ml heparin, 0.01% Tween 20, and 100 g/ml BSA)
and incubated for 30 min followed by the addition of 10 M Acrs. This mixture was incubated for 30 min
followed by the addition of 8 nM FAM-tagged NTS4B protospacer (34 bp containing only 8-bp PAM
duplex). After an incubation of 30 min the polarization measurements were made on Victor3 multilabel
plate counters (Perkin Elmer). To calculate fraction-bound values, data were normalized by setting the
lowest anisotropy to 0 and highest to 1. The curve ﬁtting was performed in GraphPad Prism using the
following equation:
Y
|DNA| |RNP| Kd|DNA| |RNP| Kd2 4 |DNA| |RNP|
2 |DNA|
Coimmunoprecipitation. Plasmids expressing NmeCas9 and each anti-CRISPR protein were cotrans-
fected into HEK293T cells. After 48 h, cell lysates were collected and bound to M2 FLAG magnetic beads
(Sigma) overnight at 4°C. The beads were washed 5 times before elution by boiling with sample buffer
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(125 mM Tris-HCl, pH 6.8, with 4% SDS, 20% [vol/vol] glycerol, and 0.004% bromphenol blue). Subse-
quent Western blotting was performed as described below.
Western blots. For estimating anti-CRISPR protein levels in cells, plasmids encoding each Acr were
transiently transfected into HEK293T cells using Polyfect (Qiagen). After 72 h, cell lysate was collected
with lysis buffer (50 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, 1 protease
inhibitor cocktail [Sigma]). Lysates were boiled with the sample buffer supplemented with 5%
2-mercaptoethanol at 95°C for 5 min before running on 15% SDS-PAGE gels (Bio-Rad). Proteins were then
transferred onto a PVDF membrane on a semidry transfer blot using the manufacturer’s instructions
(Bio-Rad). Membranes were blocked in 5% dry milk, incubated with 1:5,000 primary antibodies (anti-FLAG
raised in rabbit; Sigma) overnight, washed three times with TBST (25 mM Tris-HCl [pH 7.6], 125 mM NaCl,
1% Tween 20) for 5 min, and then incubated with HRP-conjugated secondary antibodies for detection
with X-ray ﬁlm (Kodak). For the NmeCas9 stability experiment, 150 ng of Cas9-expressing and 150 ng of
sgRNA-expressing plasmids were transiently transfected with an additional 100 ng of Acr-expressing
plasmid. For the no-sgRNA control, 150 ng of empty vector was used. Cell lysates were collected and run
on a 6% SDS-PAGE gel as described above. After transfer and blocking steps, membranes were incubated
with 1:5,000 anti-HA (mouse; Sigma) antibodies overnight and washed with TBST three times for 5 min
before incubation with secondary antibodies (ThermoFisher) for 1 h. As a loading control, 1:5,000
anti-GAPDH (rabbit; Abcam) primary antibodies and HRP-conjugated secondary antibodies against rabbit
(Bio-Rad) were used.
Targeted deep sequencing analysis. Targeted deep sequencing analyses were done as previously
described (44). Brieﬂy, we used a two-step PCR ampliﬁcation approach to produce DNA fragments for
each on-target and off-target site. In the ﬁrst step, we used locus-speciﬁc primers bearing universal
overhangs with ends complementary to the TruSeq adaptor sequences (Data Set S1). DNA was ampliﬁed
with High Fidelity 2 PCR Master Mix (NEB) using appropriate annealing temperatures for the on-target
(NTS1C) and off-target (NTS1C-OT1) sites. In the second step, the puriﬁed PCR pool was ampliﬁed with
a universal forward primer and an indexed reverse primer to reconstitute the TruSeq adaptors. Full-size
products (250 bp in length) were extracted using AMPure beads (Beckman Coulter). The puriﬁed library
was deep sequenced using a paired-end 150 bp MiSeq run. Raw deep sequencing data and the results
of statistical tests are reported in Data Set S1.
Data availability. Raw data ﬁles are available upon reasonable request. High-throughput sequenc-
ing data are available at the NCBI Sequence Read Archive (accession no. PRJNA505886).
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